Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

Author(s): Garçon N, Van Mechelen M

Abstract

The immunostimulants 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-21 are part of licensed or candidate vaccines. MPL and QS-21 directly affect the innate immune response to orchestrate the quality and intensity of the adaptive immune response to the vaccine antigens. The combination of immunostimulants in different adjuvant formulations forms the basis of Adjuvant Systems (AS) as a way to promote appropriate protective immune responses following vaccination. MPL and aluminum salts are present in AS04, and both MPL and QS-21 are present in AS01 and AS02, which are liposome- and emulsion-based formulations, respectively. The recent clinical performance of AS01-, AS02- and AS04-adjuvanted vaccines will be discussed in the context of the diseases being targeted. The licensing of two AS04-adjuvanted vaccines and the initiation of Phase III trials with an AS01-adjuvanted vaccine demonstrate the potential to develop new or improved human vaccines that contain MPL or MPL and QS-21.

Similar Articles

Saponins as vaccine adjuvants

Author(s): Kensil CR

Advances in saponin-based adjuvants

Author(s): Sun HX, Xie Y, Ye YP

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

Author(s): Ragupathi G, Gardner JR, Livingston PO, Gin DY

Potential adjuvantic properties of innate immune stimuli

Author(s): Warshakoon HJ, Hood JD, Kimbrell MR, Malladi S, Wu WY, et al

Saponin adjuvants

Author(s): Dalsgaard K

Saponin

Author(s): Campbell JB, Peerbaye YA

Immunostimulating complexes (ISCOMs) for nasal vaccination

Author(s): Hu KF, Lövgren-Bengtsson K, Morein B

Antigen delivery systems

Author(s): Kersten G, Hirschberg H

Vaccine adjuvants revisited

Author(s): Aguilar JC, Rodríguez EG

QS-21 and QS-7: purified saponin adjuvants

Author(s): Kensil CR, Wu JY, Anderson CA, Wheeler DA, Amsden J

QS-21 structure/function studies: effect of acylation on adjuvant activity

Author(s): Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR

Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats

Author(s): Marciani DJ, Kensil CR, Beltz GA, Hung CH, Cronier J, et al.